Cited by

• Similar transplant outcomes between haploidentical and unrelated donors after reduced-intensity conditioning with busulfan, fludarabine, and anti-thymocyte globulin in patients with acute leukemia or myelodysplastic syndrome.

  Choi M, Heo JY, Shin DY, Lee JY, Koh Y, Hong J, Kim I, Yoon SS, Lee JO, Bang SM. Choi M, et al. Blood Res. 2020 Mar;55(1):27-34. doi: 10.5045/br.2020.55.1.27. Epub 2020 Mar 30. Blood Res. 2020. PMID: 32269972 Free PMC article.
• Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Governs GVHD and Immunosuppression Need, Reducing Late Toxicities in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors.

  Carnevale-Schianca F, Caravelli D, Gallo S, Becco P, Paruzzo L, Poletto S, Polo A, Mangioni M, Salierno M, Berger M, Pessolano R, Saglio F, Gottardi D, Rota-Scalabrini D, Grignani G, Fizzotti M, Ferrero I, Frascione PMM, D'Ambrosio L, Gaidano V, Gammaitoni L, Sangiolo D, Saglietto A, Vassallo E, Cignetti A, Aglietta M, Fagioli F. Carnevale-Schianca F, et al. J Clin Med. 2021 Mar 11;10(6):1173. doi: 10.3390/jcm10061173. J Clin Med. 2021. PMID: 33799685 Free PMC article.
• ATG or no ATG? - survey of clinical practice in EBMT centers on behalf of the Transplant Complications Working Party of EBMT.

  Piekarska A, Czyz A, Peczynski C, Ambron P, Polge E, Moiseev I, Schoemans H, Penack O, Peric Z, Basak GW. Piekarska A, et al. Bone Marrow Transplant. 2023 Mar;58(3):337-339. doi: 10.1038/s41409-022-01889-y. Epub 2022 Dec 5. Bone Marrow Transplant. 2023. PMID: 36471107 No abstract available.
• High-dose alemtuzumab and cyclosporine vs tacrolimus, methotrexate, and sirolimus for chronic graft-versus-host disease prevention.

  Holtzman NG, Curtis LM, Salit RB, Shaffer BC, Pirsl F, Ostojic A, Steinberg SM, Schulz E, Wilder JS, Hughes TE, Rose J, Memon S, Korngold R, Gea-Banacloche JC, Fowler DH, Hakim FT, Gress RE, Bishop MR, Pavletic SZ. Holtzman NG, et al. Blood Adv. 2024 Aug 27;8(16):4294-4310. doi: 10.1182/bloodadvances.2023010973. Blood Adv. 2024. PMID: 38669315 Free PMC article. Clinical Trial.
• Recipient BCL2 inhibition and NK cell ablation form part of a reduced intensity conditioning regime that improves allo-bone marrow transplantation outcomes.

  Jiao Y, Davis JE, Rautela J, Carrington EM, Ludford-Menting MJ, Goh W, Delconte RB, Souza-Fonseca-Guimaraes F, Koldej R, Gray D, Huang D, Kile BT, Lew AM, Ritchie DS, Huntington ND. Jiao Y, et al. Cell Death Differ. 2019 Aug;26(8):1516-1530. doi: 10.1038/s41418-018-0228-y. Epub 2018 Nov 12. Cell Death Differ. 2019. PMID: 30420758 Free PMC article.